Derek Archila

Stock Analyst at Wells Fargo

(4.28)
# 415
Out of 5,124 analysts
212
Total ratings
53.85%
Success rate
14.68%
Average return

Stocks Rated by Derek Archila

argenx SE
Dec 16, 2025
Maintains: Overweight
Price Target: $1,316$1,264
Current: $801.18
Upside: +57.77%
Nurix Therapeutics
Dec 16, 2025
Maintains: Overweight
Price Target: $21$30
Current: $17.20
Upside: +74.42%
Kyverna Therapeutics
Dec 16, 2025
Maintains: Overweight
Price Target: $31$33
Current: $7.85
Upside: +320.38%
Disc Medicine
Dec 16, 2025
Maintains: Overweight
Price Target: $91$109
Current: $76.47
Upside: +42.54%
Monte Rosa Therapeutics
Dec 16, 2025
Upgrades: Overweight
Price Target: $13$22
Current: $13.96
Upside: +57.59%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $69$116
Current: $73.05
Upside: +58.80%
ORIC Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $19$25
Current: $8.09
Upside: +209.21%
Incyte
Dec 8, 2025
Maintains: Overweight
Price Target: $97$116
Current: $107.27
Upside: +8.14%
Annexon
Nov 19, 2025
Maintains: Overweight
Price Target: $14$27
Current: $5.07
Upside: +433.07%
Septerna
Nov 14, 2025
Upgrades: Overweight
Price Target: $18$28
Current: $25.45
Upside: +10.02%
Maintains: Overweight
Price Target: $76$84
Current: $72.72
Upside: +15.51%
Maintains: Equal-Weight
Price Target: $395$479
Current: $403.94
Upside: +18.58%
Maintains: Overweight
Price Target: $11$14
Current: $7.47
Upside: +87.42%
Maintains: Overweight
Price Target: $16$15
Current: $11.70
Upside: +28.26%
Maintains: Overweight
Price Target: $123$106
Current: $45.64
Upside: +132.28%
Maintains: Overweight
Price Target: $51$81
Current: $43.71
Upside: +85.31%
Maintains: Equal-Weight
Price Target: $36$30
Current: $43.73
Upside: -31.40%
Maintains: Equal-Weight
Price Target: $7$5
Current: $6.26
Upside: -20.13%
Upgrades: Overweight
Price Target: $29$32
Current: $23.75
Upside: +34.74%
Maintains: Overweight
Price Target: $5$10
Current: $2.06
Upside: +385.44%
Downgrades: Equal-Weight
Price Target: $25$1
Current: $0.72
Upside: +39.24%
Maintains: Overweight
Price Target: $44$38
Current: $26.20
Upside: +45.04%
Maintains: Equal-Weight
Price Target: $40$30
Current: $11.10
Upside: +170.27%
Maintains: Equal-Weight
Price Target: $3$2
Current: $2.06
Upside: -2.91%
Maintains: Overweight
Price Target: $289$295
Current: $209.29
Upside: +40.95%
Maintains: Equal-Weight
Price Target: $6$5
Current: $1.84
Upside: +172.48%
Maintains: Equal-Weight
Price Target: $27$26
Current: $30.75
Upside: -15.43%
Initiates: Overweight
Price Target: $17
Current: $16.50
Upside: +3.03%
Maintains: Overweight
Price Target: $91$129
Current: $99.00
Upside: +30.30%
Maintains: Equal-Weight
Price Target: $16$15
Current: $3.40
Upside: +341.83%
Maintains: Equal-Weight
Price Target: $12$14
Current: $23.85
Upside: -41.30%
Maintains: Overweight
Price Target: $47$45
Current: $25.60
Upside: +75.78%
Downgrades: Hold
Price Target: $37$20
Current: $3.72
Upside: +438.36%
Initiates: Buy
Price Target: $18
Current: $4.56
Upside: +294.74%
Downgrades: Hold
Price Target: $298$193
Current: $32.54
Upside: +493.21%
Reiterates: Buy
Price Target: $61$41
Current: $71.45
Upside: -42.62%
Maintains: Hold
Price Target: $480$160
Current: $13.56
Upside: +1,079.94%
Downgrades: Hold
Price Target: $180$60
Current: $17.00
Upside: +252.94%
Downgrades: Perform
Price Target: $29
Current: $8.13
Upside: +256.70%
Maintains: Outperform
Price Target: $34$50
Current: $1.24
Upside: +3,948.58%
Maintains: Outperform
Price Target: $32$51
Current: $21.83
Upside: +133.62%
Initiates: Outperform
Price Target: $88
Current: $14.65
Upside: +500.89%
Initiates: Market Perform
Price Target: n/a
Current: $25.14
Upside: -
Downgrades: Perform
Price Target: n/a
Current: $32.03
Upside: -